ランキング価格はじめての方へ
  1. 米国企業
  2. MANNKIND CORP
  3. Raw

MANNKIND CORPMNKD

時価総額
$18.3億
PER
吸入薬の新興企業。iSPERSE技術と吸入インスリンAfrezzaを展開。2024年7月にR&D資産を買収、2022年5月にV‑Goを買収。従業員407人、長期資産は約9950万ドル、米国・中国で展開。
概要財務
サマリーテーブルに戻る
2011年
12月31日		2012年
12月31日		2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日		2024年
12月31日
Net income (loss)--------87-52-57-81-87-1228
Stock-based compensation1251381834995576712131821
Loss on settlement of debt-----172-2-14-0-17---20
Interest on liability for sale of future royalties------------016
Depreciation and amortization1121271411913443124657
Write-off of inventory----36-32-12254
Amortization of right-of-use assets-----------312
Amortization of debt discount and issuance costs------------22
Loss on available-for-sale securities------------1-0-2
Loss on estimated returns of acquired product-------------1
Loss on disposal of fixed assets--------------1
Sold portion of royalty revenue-------------10
Gain on bargain purchase-------------5
Net (accretion) amortization of investments-------------1-5
(Gain) loss on foreign currency transaction-----3-1442-875-24
Other, net00-00--0-00-0-0--000
Non Cash Interest On Financing Liability------------0-
Accounts receivable, net-----021-11112-2-3
Inventory---10262331146113
Prepaid expenses and other current assets13415-130-1-00001697
Other assets0001-0-0-0-01-00-1-04
Accounts payable44348-124-2-1114-1-3
Accrued expenses and other current liabilities2035392-12032339-17-3
Deferred revenue---------7-6-151939-15
Recognized loss on purchase commitments---------4-5-6-6-9-3
Operating lease liabilities---------2-1-2-3-2-2
Deposits from customer----------5-5--
Net cash provided by (used in) operating activities-124-120-129-----38-88-28-62-813443
Purchase of held-to-maturity debt securities----------1967579274
Proceeds from maturities of held-to-maturity securities----------59107119135
Purchase of available-for-sale securities----------35-7
Proceeds from maturities of available-for-sale securities-------------58
Purchase of property and equipment32732833624101-0311184210
Acquisition of V-Go-----------15--
Proceeds from insurance claim------------00
Net cash (used in) provided by investing activities-3-1-8-----0-2315-1525-2-97
Proceeds from sale of future royalties------------150-
Issuance costs associated with sale of future royalties------------4-
Principal and early extinguishment payments on senior convertible notes--------11----88
Principal and early extinguishment payments on MidCap credit facility-------------37
Principal and early extinguishment payments on Mann Group convertible note222-----38-35--9
Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options------------106
Proceeds from market price stock purchase plan and employee stock purchase plan-----------323
Milestone payment----34---2-5111
Principal payment on financing liability------------00
Proceeds from at-the-market-offering--------3232207-
At The Market Issuance-------001000-
Issuance costs associated with at-the-market offering----1-0---3---
Net cash (used in) provided by financing activities1,8061,9862,131----61705027021137-137
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH-------23-413757-54169-191
Interest paid in cash------8424-91818
Income Taxes Paid, Net-------------4
Payments of senior convertible note principal through common stock issuances-------------116
Assumption of right-of-use-asset and operating lease liability-------------10
Non-cash acquisition of intangible asset-------------4
Amortization of liability for sale of future royalties-------------4
Reclassification Of Credit Facility From Long-term To Current------------27-
Reclassification of investments from long-term to current-----------836-
Capital Expenditures Incurred but Not yet Paid---------0-122
Non-cash acquisition of property and equipment-------------1
Right-of-use asset modification-----------41-
Goodwill adjustment for a net reduction in liabilities------------0-
Receivable for insurance claim on damaged equipment------------0-
Accrued issuance costs associated with liability for sale of future royalties------------0-
Payments on debt and interest through common stock issuance-----------100-
Reclassification Of Convertible Notes And Interest Receivable-----------7--
Issuance of common stock under employee stock purchase plan--------11----
Addition of right-of-use-asset--------5--2--
Contingent milestone liability-----------1--
Issuance Of Warrants Associated With Credit Facility--------20----